Business Wire

CA-SYSDIG

13.1.2022 17:56:06 CET | Business Wire | Press release

Share
​​Creator of Wireshark Joins Sysdig to Extend the Open Source Project for Cloud Security

Sysdig, Inc., the unified container and cloud security leader, today announced that Gerald Combs, the Wireshark creator and project leader, has joined the company. Wireshark, an open source tool, is the world’s foremost and widely-used traffic protocol analyzer with more than 60 million downloads in the last 5 years, an average of one million per month. Loris Degioanni, CTO and Founder of Sysdig, partnered with Gerald to launch Wireshark more than 15 years ago. Gerald joins Sysdig’s open source team, which is a significant contributor to many open source projects, including Falco, eBPF, Sysdig open source, Sysdig Inspect, and other tools and libraries. With Gerald joining, Sysdig assumes responsibility for sponsoring and managing the Wireshark community and extending Wireshark’s use cases to the cloud ecosystem.

Wireshark is an open source GUI network package capturing tool that enables teams to monitor network traffic, learn protocols and packet basics, and troubleshoot network problems. For network admins, Wireshark is the de facto standard for checking health and security at a microscopic level. Wireshark takes packet captures and saves them for later viewing. Teams can filter through that traffic to find evidence from an incident. With more than 1,900 contributors, the number of integrations continues to expand. Adoption is broad as Wireshark can be used consistently across nearly any environment, including Windows, Linux, and macOS, among others.

“It’s amazing to see the lasting heritage of Wireshark, led by Gerald. You can guarantee most of the Fortune 2000 are actively using Wireshark,” said Loris Degioanni, CTO and Founder, Sysdig. “I am excited to be reunited with Gerald and to advance the project in the same way Sysdig supports Falco and the Sysdig open source project. This move ensures Wireshark will continue to innovate. Our goal at Sysdig is to empower Wireshark.”

The Importance of Healthy Open Source Projects

The Log4j and OpenSSL vulnerabilities have shown that large and small organizations rely on open source projects and major issues arise when critical vulnerabilities are found in these tools. Log4j spotlighted the importance of maintaining open source projects. Continuing to maintain the project’s health is of the utmost importance considering the widespread adoption of Wireshark.

The Wireshark Story

While studying network analyzers and creating a popular open source tool while working on his PhD in Italy, Loris was invited to the United States to do research on packets, which is where he met Gerald. Gerald joined Loris at CACE Technologies in the early 2000’s, where they collaborated and grew Wireshark. CACE Technologies was later acquired and since that time, Gerald has focused on growing the tool and ensuring Wireshark and its community have the resources needed to thrive.

“I am excited to be reunited with Loris and explore the opportunity we have to expand Wireshark to the cloud,” said Gerald Combs, Director of Open Source Projects, Sysdig. “My move to Sysdig and the subsequent move for Wireshark will give Wireshark the corporate sponsor it needs to continue moving forward. This is a significant milestone for Wireshark and with Sysdig’s backing, we will have the assistance we need to continue to evolve use cases for Wireshark.”

The Wireshark Future

Sysdig will ensure the community has the backing it needs, including supporting Gerald as the leader of the community, ensuring Wireshark has the resources needed to operate, and sponsoring SharkFest. Sysdig has an open source team that will contribute to Wireshark. Reunited, Gerald and Loris will investigate new innovative ways to address challenges with securing the cloud.

Sysdig’s Commitment to Open Source

Sysdig was founded as an open source company and the Sysdig platform was built on an open source foundation to address the security challenges of modern cloud applications. Open source Sysdig and Falco are projects that were created by Sysdig to leverage deep visibility as a foundation for security, and they have become standards for container and cloud threat detection and incident response. Falco, which was contributed to the CNCF in 2018, is now an incubation-level hosted project with more than 40 million downloads.

Resources

About Sysdig

Sysdig is driving the standard for securing the cloud, empowering organizations to confidently secure containers, Kubernetes, and cloud services. The Sysdig platform enables teams to secure the build, detect and respond to runtime threats, and continuously manage cloud configurations, permissions and compliance. Sysdig is a SaaS platform built on an open source stack that includes Falco and Sysdig open source, the open standards for runtime threat detection and response. The largest and most security conscious companies rely on Sysdig for container and cloud security. sysdig.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye